juststock/iStock via Getty Images Biogen ( NASDAQ: BIIB ) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders for targets in Alzheimer’s and other diseases. Under.
